Abstract
Background
In our study, diagnostic and demographic characteristics of patients diagnosed with RPGN by biopsy, clinical and laboratory findings in our country were investigated.
Methods
Data were obtained from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group database. Demographic characteristics, indications for biopsy, diagnosis of the glomerular diseases, comorbidities, laboratory and biopsy findings of all patients were recorded. According to their types, RPGN patients were classified as type 1 (anti-GBM related), type 2 (immuncomplex related) and type 3 (pauci-immune).
Results
Of 3875 patients, 200 patients with RPGN (mean age 47.9 ± 16.7 years) were included in the study which constitutes 5.2% of the total glomerulonephritis database. Renal biopsy was performed in 147 (73.5%) patients due to nephritic syndrome. ANCA positivity was found in 121 (60.5%) patients. Type 1 RPGN was detected in 11 (5.5%), type 2 RPGN in 42 (21%) and type 3 RPGN in 147 (73.5%) patients. Median serum creatinine was 3.4 (1.9–5.7) mg/dl, glomerular filtration rate was 18 (10–37) ml/min/1.73m2 and proteinuria 2100 (1229–3526) mg/day. The number of crescentic glomeruli ratio was ratio 52.7%. It was observed that urea and creatinine increased and calcium and hemoglobin decreased with increasing crescentic glomerular ratio.
Conclusions
Our data are generally compatible with the literature. Advanced chronic histopathological findings were prominent in the biopsy of 21 patients. Early biopsy should be performed to confirm the diagnosis of RPGN and to avoid unnecessary intensive immunosuppressive therapy. In addition to the treatments applied, detailed data, including patient and renal survival, are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J. 2015;8:143–50. https://doi.org/10.1093/ckj/sfv008.
Kantauskaite M, Laucyte-Cibulskiene A, Miglinas M. Histopathological classification-A prognostic tool for rapidly progressive glomerulonephritis. Medicina (Kaunas). 2018. https://doi.org/10.3390/medicina54020017.
Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, Yin H, Chen J, Pu J, Peng Z, Peng W, Li X, Xiao X, Zhou Q, Zhong Y, Xiao P. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019;18:3984–90. https://doi.org/10.3892/etm.2019.8023.
Jennette JC, Thomas DB. Crescentic glomerulonephritis. Nephrol Dial Transplant. 2001;16:80–2.
Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 1987;31:790–4. https://doi.org/10.1038/ki.1987.67.
Couser WG. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis. 1988;11:449–64. https://doi.org/10.1016/s0272-6386(88)80079-9.
Wall N, Harper L. Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol. 2012;8:523–32. https://doi.org/10.1038/nrneph.2012.107.
de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8:1709–17. https://doi.org/10.2215/CJN.01020113.
Ozturk S, Sumnu A, Seyahi N, Gullulu M, Sipahioglu M, Artan S, Bicik Z, Kutlay S, Keles M, Oygar D, Odabas AR, Kayatas M, Dursun B, Sayarlioglu H, Trablus S, Taymez DG, Ozdemir AA, Sahin GM, Altun B, Azak A, Altintepe L, Suleymanlar G, Koc M, Selcuk Y, Kazancioglu R, Erkoc R, Gursu M, Kucuk M, Akcaoglu SA, Yıldız A, Unal A, Akarsu O, Ates K, Cankaya E, Turkmen A. Demographic and clinical characteristics of primary glomerular diseases in Turkey. Int Urol Nephrol. 2014;46:2347–55. https://doi.org/10.1007/s11255-014-0838-3.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Can O, Gumrukcu G, Vardar Aker F, Guren AK, Bilek G, Apaydin S, Manga SG. Rapidly pregressive glomerulonephritis: a single-center experiences. Turk Nephrol Dial Transpl. 2018;27:249–53. https://doi.org/10.5262/tndt.2018.3131.
Tang Z, Wu Y, Wang Q, Zeng C, Yao X, Hu W, Chen H, Liu Z, Li L. Clinical spectrum of diffuse crescentic glomerulonephritis in Chinese patients. Chin Med J (Engl). 2003;116:1737–40.
Andrassy K, Kuster S, Waldherr R, Ritz E. Rapidly progressive glomerulonephritis: analysis of prevalence and clinical course. Nephron. 1991;59:206–12. https://doi.org/10.1159/000186552.
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–77. https://doi.org/10.1046/j.1523-1755.2003.00843.x.
Chen S, Tang Z, Xiang H, Li X, Chen H, Zhang H, Hu W, Zeng C, Liu Z. Etiology and outcome of crescentic glomerulonephritis from a single center in china: a 10-year review. Am J Kidney Dis. 2016;67:376–83. https://doi.org/10.1053/j.ajkd.2015.07.034.
Chen M, Cui Z, Zhao MH. ANCA-associated vasculitis and anti-GBM disease: the experience in China. Nephrol Dial Transplant. 2010;25:2062–5. https://doi.org/10.1093/ndt/gfq134.
Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, Ihara T, Kobayashi M, Itabashi M, Kitagawa K, Hirahashi J, Kimura K, Matsuo S. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20(3):322–41. https://doi.org/10.1007/s10157-015-1218-8.
Gupta R, Singh L, Sharma A, Bagga A, Agarwal SK, Dinda AK. Crescentic glomerulonephritis: a clinical and histomorphological analysis of 46 cases. Indian J Pathol Microbiol. 2011;54:497–500. https://doi.org/10.4103/0377-4929.85081.
Vizjak A, Rott T, Koselj-Kajtna M, Rozman B, Kaplan-Pavlovcic S, Ferluga D. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity. Am J Kidney Dis. 2003;41:539–49. https://doi.org/10.1053/ajkd.2003.50142.
Malik SI, Idrees MK, Naseem K, Sadiq S, Raza SH, Ahmad FU. Pattern of biopsy-proven kidney diseases: experience of a teaching hospital in Bahawalpur. Pakistan Saudi J Kidney Dis Transpl. 2019;30:1144–50. https://doi.org/10.4103/1319-2442.270271.
Navaratnarajah A, Sambasivan K, Cook TH, Pusey C, Roufosse C, Willicombe M. Predicting long-term renal and patient survival by clinicopathological features in elderly patients undergoing a renal biopsy in a UK cohort. Clin Kidney J. 2019;12:512–20. https://doi.org/10.1093/ckj/sfz006.
Lin W, Chen M, Cui Z, Zhao MH. The immunopathological spectrum of crescentic glomerulonephritis: a survey of 106 patients in a single Chinese center. Nephron Clin Pract. 2010;116:65–74. https://doi.org/10.1159/000314665.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. All authors contributed to study material preparation, data collection. Analysis; ZA, KT and SO. The first draft of the manuscript was written by ZA and KT. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared that no confict of interest exists.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number 1164/2011) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Aydin, Z., Turkmen, K., Dede, F. et al. Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group. Clin Exp Nephrol 25, 173–183 (2021). https://doi.org/10.1007/s10157-020-01978-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-020-01978-6